RAYMOND J. LAND - Corporate Board Profile

Anika Therapeutics, Inc.

Filing Date	Source Excerpt
2006-04-24	Mr. Land joined the Board of Directors of Anika Therapeutics in January 2006. The Audit Committee members include Mr. Land (Chairperson). For fiscal year 2005, each director who was not an employee of Anika Therapeutics received a director's fee of $20,000.
2007-04-27	Mr. Land joined the Board of Directors of Anika Therapeutics in January 2006. The current members of the Audit Committee are Mr. Land, as Chairperson, Dr. Bower and Mr. Wheeler. The Nominating Committee members include Mr. Land. The following table summarizes the compensation paid by the Company to non-employee Directors for the fiscal year ended December 31, 2006. Raymond J. Land Fees Earned or Paid in Cash ($): $28,000, Stock Awards ($): 0, Option Awards ($): 25,722, Total ($): 53,722.
2008-04-25	Mr. Land joined the Board of Directors of Anika Therapeutics in January 2006. The current members of the Audit Committee are Mr. Land, as Chairperson, Dr. Bower, and Mr. Moran. The Governance and Nominating Committee members include Mr. Land. For fiscal year 2007, each director who was not an employee of Anika Therapeutics received a director's fee of $20,000. Raymond J. Land received $26,000.
2009-04-28	Mr. Land joined the Board of Directors of Anika Therapeutics in January 2006. The current members of the Audit Committee are Mr. Land, as Chairperson, Dr. Bower, and Mr. Moran. The current members of the Governance and Nominating Committee are Mr. Wheeler, as Chairperson, and Messrs. Moran and Land. The following table summarizes the compensation paid by the Company to non-employee Directors for the year ended December 31, 2008. Raymond J. Land received $37,250 in fees and $29,954 in stock awards, totaling $67,204.
2010-04-22	Mr. Land is Chairman and designated financial expert on the Audit Committee. The following table summarizes the compensation paid by the Company to non-employee Directors for the year ended December 31, 2009. Raymond J. Land: Fees Earned or Paid in Cash $42,500, Stock Awards $22,875, Total $65,375.
2011-04-28	Mr. Land is Chairman of the Audit Committee and serves on the Governance and Nominating Committee. For 2010, he received $43,500 in fees and $29,994 in stock awards, totaling $73,494.
2012-04-25	Mr. Land became a member of Anika Therapeutics’ Board of Directors in January 2006. He serves as Chairman of the Audit Committee and is a member of the Governance and Nominating Committee. The following table summarizes the compensation paid by the Company to non-employee Directors for the year ended December 31, 2011. Raymond J. Land received $43,500 in fees earned or paid in cash and $29,994 in stock awards, totaling $73,494.
2013-04-23	Mr. Land became a member of Anika Therapeutics’ Board of Directors in January 2006. ... He serves as the Chairman and designated financial expert on the Audit Committee. ... The current members of the Audit Committee are Mr. Land, as Chairperson, Dr. Bower, and Mr. Moran. ... The current members of the Governance and Nominating Committee are Mr. Wheeler, as Chairperson, and Messrs. Moran and Land. ... The following table summarizes the compensation paid by the Company to non-employee Directors for the year ended December 31, 2012. ... Raymond J. Land Fees Earned or Paid in Cash $44,000, Stock Awards $29,994, Total $73,994.
2014-04-23	Mr. Land became a member of Anika Therapeutics’ Board of Directors in January 2006. Mr. Land's qualifications for membership on the Company's Board include his extensive prior experience as chief financial officer at multiple companies, including several in the life science industry. The current members of the Audit Committee are Mr. Land, as Chairperson, Dr. Bower, and Mr. Moran. The Governance and Nominating Committee current members are Mr. Wheeler, as Chairperson, and Messrs. Moran and Land. The following table summarizes the compensation paid by the Company to non-employee Directors for the year ended December 31, 2013. Raymond J. Land Fees Earned or Paid in Cash $41,500, Stock Awards $30,001, Total $71,501.
2015-04-23	Raymond J. Land became a member of the Board of Directors in January 2006. He serves as Chairperson and designated financial expert on the Audit Committee. The current members of the Audit Committee are Mr. Land as Chairperson. The Governance and Nominating Committee includes Mr. Land. The following table summarizes the compensation we paid to non-employee directors for the year ended December 31, 2014. Raymond J. Land: Fees Paid in Cash $60,500, Stock Awards $59,973, Total $120,473.
2016-04-20	Raymond J. Land became a member of the Board of Directors in January 2006. He serves as Chairperson of the Audit Committee and is a member of the Governance and Nominating Committee. For 2015, he received $65,000 in cash fees and $59,972 in stock awards, totaling $124,972.
2017-04-28	Raymond J. Land became a member of the Board of Directors in January 2006. He also serves as chairman of the Board of Directors and interim Chief Financial Officer of BioAmber, Inc., a publicly traded company developing chemicals from renewable feedstocks, and a director and chairman of the Audit Committee of Mountain View Pharmaceuticals, Inc., a privately held company specializing in biopharmaceuticals. From 2008 through 2010, Mr. Land served as the Senior Vice President and Chief Financial Officer of Clarient, Inc., an advanced molecular diagnostics company. From June 2007 to June 2008, he was the Senior Vice President and Chief Financial Officer of Safeguard Scientifics, Inc., a venture capital firm. Prior to Safeguard Scientifics, Inc., Mr. Land held executive management and Chief Financial Officer positions at Medcenter Solutions, Inc., a pharmaceutical marketing company where he was also a board member, and Orchid Cellmark, a provider of DNA testing services. Mr. Land previously served as Senior Vice President and Chief Financial Officer for Genencor International, Inc., a biotechnology company focusing on bioproducts and healthcare, from 1997 until its acquisition in April 2005. From 1991 to 1996, he served as Senior Vice President and Chief Financial Officer for West Pharmaceutical Services, Inc. Previously, Mr. Land was with Campbell Soup Company, Inc. where for nine years he held increasingly senior financial positions and also served as General Manager of a frozen food division. Prior to joining Campbell Soup, he was with Coopers and Lybrand for nine years. Mr. Land is a retired Certified Public Accountant and has a B.S. degree in accounting and finance from Temple University. Mr. Land's qualifications for membership on the Board include his extensive prior experience as chief financial officer at multiple companies, including several in the life science industry. He serves as the Chairperson and designated financial expert on the Audit Committee and as a member of the Governance and Nominating Committee.
2018-04-17	Raymond J. Land became a member of the Board in January 2006. He serves as the Chairperson and designated financial expert on the Audit Committee and as a member of the Governance and Nominating Committee. The following table summarizes the compensation we paid to non-employee directors for 2017. Raymond J. Land: Fees Earned or Paid in Cash ($) 65,000, Stock Awards ($) 99,959, Total ($) 164,959.
2019-04-25	Raymond J. Land Anika Board Service: ·Tenure: 13 years ·Committees: ○ Audit (Chair, Financial Expert) ○ Governance and Nominating INDEPENDENT Age: 74 Director Compensation Raymond J. Land Fees Earned or Paid in Cash ($): 65,000 Stock Awards ($): 99,950 Total ($): 164,950
2020-04-29	Raymond J. Land Age: 75 Director since 2006 Committees: Audit (Chair, Financial Expert), Governance and Nominating 2019 Director Compensation: $199,980 Independent Director
2021-04-30	Raymond J. Land Age: 76 Director since January 2006 Independent Audit Committee Chair Compensation Committee member 2020 Director Compensation: Fees earned or paid in cash $75,810, Stock awards $174,999, Total $250,809